What Mesulid Treats: Main Uses and Benefits

Mesulid (Nimesulide) is primarily applied across domains where additional symptomatic support is needed. Its therapeutic function is to provide supportive symptomatic relief by addressing symptoms related to pain, inflammation, and fever. The medicine is commonly used in situations involving certain distressing symptoms, including for managing acute pain and the symptomatic management of primary dysmenorrhoea (menstrual cramps) in adolescents and adults.

Relief from Acute Pain and Inflammation

This medication is commonly applied across conditions where symptoms may intensify temporarily related to inflammatory states, such as those that arise from musculoskeletal injuries like sprains and strains, conditions involving episodic or fluctuating manifestations related to joints, and specific post-procedural discomfort. The medication may assist with a supportive analgesic and anti-inflammatory effect, which helps ease the overall symptom burden and contributes to comfort during periods of heightened symptoms.

---

Symptomatic Focus: Inflammatory Pain

Mesulid is commonly used to help with symptoms related to inflammatory or irritative states and systemic imbalance, supporting multiple symptom-focused domains.

The eligibility for Mesulid (Nimesulide) use is strictly regulated, defining clear exclusions based on age, organ function, and specific medical history. The European Medicines Agency (EMA) requires significant restrictions to minimize potential risks.

Age-Related Eligibility

• Contraindicated: Children under 12 years of age must not use this medicine.
• Eligible: Adolescents (12–18 years) and Adults are eligible under the specific restrictions outlined below.

Absolute Contraindications (Must Not Use)

• Patients with severe renal impairment, any degree of hepatic impairment, or severe heart failure.
• History of hepatotoxic reactions to Nimesulide or hypersensitivity to other Non-steroidal Anti-inflammatory Drugs (NSAIDs).
• Patients with active gastric/duodenal ulcers, a history of recurrent gastrointestinal bleeding, or severe coagulation disorders.

Pregnancy and Use Restrictions

• Contraindicated: Use during the third trimester of pregnancy and while breastfeeding is prohibited.
• Restrictions: Use must be limited to a maximum of 15 days and the medicine must only be prescribed as a second line treatment.

Interactions with other medicines and products

The use of Mesulid (Nimesulide) may result in clinically significant interactions with several categories of medicinal products, primarily due to an increased risk of adverse effects or alterations in drug concentrations.

Interacting Product Category	Interaction Mechanism and Outcome
Anticoagulants (e.g., Warfarin) & Antiplatelet Agents (e.g., Aspirin)	Combination is not recommended due to an enhanced risk of bleeding and hemorrhagic complications. Coagulation status should be monitored closely if concurrent use is unavoidable.
Other NSAIDs and Hepatotoxic Drugs	Contraindicated. Concomitant exposure to other potentially liver-toxic substances, including other nonsteroidal anti-inflammatory drugs and alcohol, must be strictly avoided due to the increased risk of severe hepatic reactions.
Corticosteroids	Increased risk of gastrointestinal ulceration or bleeding.
Diuretics, ACE Inhibitors, & Angiotensin II Antagonists (AIIA)	Mesulid can reduce the effectiveness of these drugs (antihypertensive and diuretic effects) and, particularly in elderly or dehydrated patients, may lead to a deterioration of renal function, including the possibility of acute renal failure. Renal function monitoring is required.
Lithium	NSAIDs, including Mesulid, can reduce the renal clearance of Lithium, leading to elevated plasma levels and potential toxicity. Lithium levels must be monitored closely during combination therapy.
Highly Plasma Protein Bound Drugs	Mesulid is extensively protein-bound and may be displaced by or displace other highly bound drugs (e.g., Phenytoin, Fenofibrate), which could lead to increased plasma concentrations and potential toxicity of the displaced drug.

Mesulid, containing the active substance nimesulide, exerts its primary pharmacodynamic action as a selective inhibitor of the enzyme cyclooxygenase-2 (COX-2). This interaction prevents the conversion of the precursor arachidonic acid into prostaglandin H2, thereby decreasing the overall synthesis of downstream prostaglandins, which are lipid mediators. COX-2 is an inducible isoform whose expression is upregulated at sites of cellular and tissue distress. The resulting systemic modulation is a reduction in the total circulating load of these prostanoid mediators.

Additionally, Mesulid exhibits a multi-factorial mechanism by inhibiting the release of superoxide anions from activated neutrophils, exhibiting scavenging activity against certain reactive oxygen species, and modulating the activity of proteolytic enzymes like matrix metalloproteinases (MMPs). These intracellular consequences further influence tissue-level cellular processes by limiting the degradation of the extracellular matrix and restricting oxidative stress within the affected area. This combined molecular action modifies overall inflammatory signaling and related physiological responses.

Administration Guidelines for Mesulid (Nimesulide)

Systemic use of Mesulid, which contains the active substance Nimesulide, is governed by specific administration rules. These guidelines specify the route, dose, frequency, and duration of use.

---

Administration Detail	Requirement
Route of Administration	Primarily Oral (tablets, granules) or Rectal (suppositories) for systemic effect. Topical formulations are also available.
Standard Dosing Schedule	The adult systemic dose is 100 mg per intake. The maximum recommended total daily dose is 200 mg.
Frequency and Timing	The standard regimen is twice daily (b.i.d.). Oral formulations must be taken after meals.
Maximum Duration	Systemic treatment must not exceed a maximum duration of 15 days.

---

Procedural Structure and Population Rules

Step Sequence: The protocol involves the administration of a 100 mg dose after a meal, repeated twice daily, and the entire course must not continue beyond the 15-day limit. Granules or powder must be prepared as an oral suspension before ingestion.

Age-Group Administration: Dosage adjustments are generally not required for adolescents (12–18 years) or older adults. However, Nimesulide is contraindicated for use in children under 12 years of age. Additionally, no dose modification is necessary for patients with mild to moderate kidney impairment (creatinine clearance 30-80 mL/min). The medicine is utilized as a second-line treatment after other options have been considered.

Research Evidence / Overview of Studies for Mesulid (Nimesulide)

This section provides an overview of the research and clinical studies that have studied Mesulid (Nimesulide) for its authorized uses, explaining the types of evidence available and where limitations exist. This information comes from official regulatory reviews and scientific literature.

---

Evidence for Use in Acute Pain and Symptomatic Relief

The research exploring Mesulid's use in short-term pain relief includes a large number of short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time in adults and adolescents with painful conditions characterized by fluctuating or episodic manifestations, such as those that follow an injury or surgical procedure. In these trials, Mesulid was evaluated in settings that compared it to an inactive substance (placebo) or to other common pain-relieving medicines.

Researchers monitored several outcomes related to physical discomfort, including measurable changes in pain intensity using standardized patient-reported scales. Trials also examined the speed at which pain relief was first observed in study participants. Findings describe patterns observed in the studies, and research monitored changes measured during the study period when compared to the control groups.

A key limitation of this research is that follow-up durations were limited by the need to study Mesulid only for its strictly short-term use. Regulatory requirements mandate that Mesulid only be used for a maximum of 15 days, meaning there is limited information for long-term outcomes. This limitation results in an absence of data regarding long-term effects or patterns if the medicine were used repeatedly or for chronic pain management.

---

Evidence for Use in Primary Dysmenorrhoea

For managing primary dysmenorrhoea (menstrual cramps), Mesulid was studied for its application during episodes of heightened symptom activity. The evidence primarily consists of short-term controlled trials and subsequent reviews that focused on outcomes capturing phases of heightened symptom activity during the menstrual cycle.

Studies examined how patient-reported outcomes describing perceived discomfort changed when Mesulid was observed in comparison to placebo and other NSAIDs. Research describes patterns related to changes in self-reported pain scores and variations in the use of additional pain medication among different treatment groups.

What remains uncertain is the consistency of findings when comparing Mesulid to every other similar medicine for this condition. The research contributes to the broader evidence landscape regarding short-term changes during menstrual periods. The results apply only to the populations studied and follow-up durations were limited to the course of one or two menstrual cycles.

---

Gaps and Uncertainty in the Research Record

While substantial research describes the acute effects, the evidence highlights what is known — and what is still uncertain. A key limitation is that long-term effects are not fully established, which is consistent with the drug being authorized only for short-term use. Consequently, the research provides limited information for long-term outcomes or cumulative effects over years. Furthermore, data for certain groups remain insufficient, meaning that knowledge about Mesulid's application in specific subgroups or chronic inflammatory settings certainty remains low.

Common questions about Mesulid (FAQ)

---

Q: What is Mesulid used to treat?

A: According to official product information, Mesulid (Nimesulide) is authorized for use in the short-term treatment of acute pain and for the symptomatic relief of primary dysmenorrhoea (menstrual pain). This medicine is generally prescribed only after other treatment options have been considered, as it is restricted to use as a second-line choice.

---

Q: What is the difference between Mesulid and Nimesulide?

A: Mesulid is the registered trade name or brand name used for the product. The active pharmaceutical ingredient contained within the medicine is called Nimesulide. Therefore, when the drug is taken, the patient receives the active substance Nimesulide.

---

Q: Can Mesulid make me drowsy or affect my ability to drive?

A: Official product information indicates that some individuals may experience side effects such as dizziness, vertigo, or somnolence (drowsiness) while taking this medicine. Regulatory warnings indicate that individuals experiencing these effects should not drive or operate complex machinery. Drowsiness is a reported adverse effect, especially in cases where the medicine is taken at higher-than-recommended amounts.

---

Q: What should I do if I miss a dose of Mesulid?

A: If a regular dose of Mesulid is forgotten, the official product information advises taking the dose as soon as it is remembered. If it is already close to the time for the next scheduled dose, official instructions advise skipping the missed dose and continuing with the next scheduled dose as usual. The product information specifically cautions against taking a double dose to make up for a missed dose.

How to Store and Dispose of Mesulid (Nimesulide)

Official regulatory information requires Mesulid to be stored in its original container at room temperature in a cool, dry place. The medication must be actively protected from heat, air, light, and moisture to prevent degradation. Due to the toxicity classification of Nimesulide, government mandates require it to be stored out of reach and sight of children and pets and often specify the precaution to store locked up.

For disposal, the primary method is using an authorized drug take-back program. If this option is unavailable, the medicine must be discarded with household trash after being mixed with an undesirable substance (like dirt or used coffee grounds) and sealed in a container; pills must not be crushed. It is strictly prohibited for the product to be disposed of by flushing or allowing it to enter sewers or ground water.